TABLE 1.
Patient characteristics.
| Patient characteristics | Relapsed/refractory group (n = 37) | Reinduction group (n = 21) |
|---|---|---|
| Male gender | 17 (46%) | 9 (43%) |
| Median age in years | ||
| At diagnosis | 62 (32–86) | 64 (50–91) |
| At the start of venetoclax therapy | 69 (45–89) | 65 (50–91) |
| Median time to venetoclax | 4.7 years | 2.6 months |
| ISS stage at the start of venetoclax therapy | ||
| 1 | 5 (14%) | 11 (52%) |
| 2 | 6 (16%) | 1 (5%) |
| 3 | 21 (57%) | 9 (43%) |
| Adverse prognostic factors | ||
| del(17p) | 12 (32%) | 6 (29%) |
| amp(1q21) | 21 (57%) | 8 (38%) |
| GFR <45 ml/min | 11 (30%) | 5 (24%) |
| Prior therapy | ||
| Median lines of treatment | 4 (1–12) | 1 (1–2) |
| Single class refractory | 0 (0%) | 2 (10%) |
| Double class refractory | 23 (62%) | 5 (24%) |
| Triple class refractory | 14 (38%) | 0 (0%) |